.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
AstraZeneca
Daiichi Sankyo
Cerilliant
Moodys
Deloitte
Johnson and Johnson
Express Scripts
Mallinckrodt
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

Abbvie Endocrine Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ABBVIE ENDOCRINE INC, and when can generic versions of ABBVIE ENDOCRINE INC drugs launch?

ABBVIE ENDOCRINE INC has six approved drugs.

There are four US patents protecting ABBVIE ENDOCRINE INC drugs.

There are one hundred and seven patent family members on ABBVIE ENDOCRINE INC drugs in forty-one countries.

Summary for Abbvie Endocrine Inc

International Patents:107
US Patents:4
Tradenames:3
Ingredients:1
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-002May 30, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-001Dec 22, 1995RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020708-001Mar 7, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020011-001Oct 22, 1990DISCNYesNo► Subscribe► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-003Jun 17, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020011-002Oct 26, 1995RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOT-PEDleuprolide acetateINJECTABLE;INJECTION020263-006Jan 21, 1994RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abbvie Endocrine Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION019732-001Jan 26, 1989► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION019732-001Jan 26, 1989► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOT-PEDleuprolide acetateINJECTABLE;INJECTION020263-006Jan 21, 1994► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-001Dec 22, 1995► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020517-002May 30, 1997► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOT-PEDleuprolide acetateINJECTABLE;INJECTION020263-006Jan 21, 1994► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION020011-001Oct 22, 1990► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOT-PEDleuprolide acetateINJECTABLE;INJECTION020263-003Apr 16, 1993► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOT-PEDleuprolide acetateINJECTABLE;INJECTION020263-007Aug 15, 2011► Subscribe► Subscribe
Abbvie Endocrine IncLUPRON DEPOTleuprolide acetateINJECTABLE;INJECTION019732-001Jan 26, 1989► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Abbvie Endocrine Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,713,595Sustained-release composition and method for producing the same► Subscribe
5,851,451 Production of microspheres► Subscribe
9,617,303Sustained-release composition and method for producing the same► Subscribe
8,246,987Controlled release composition and method of producing the same► Subscribe
8,067,030Controlled release composition and method of producing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abbvie Endocrine Inc Drugs

Country Document Number Estimated Expiration
TaiwanI481424► Subscribe
Georgia, Republic ofP20125597► Subscribe
Germany69622006► Subscribe
Austria305772► Subscribe
Canada2192782► Subscribe
Tunisia2009000197► Subscribe
South Korea20090020708► Subscribe
China1535168► Subscribe
China1292796► Subscribe
Poland204903► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Healthtrust
Accenture
Teva
QuintilesIMS
Colorcon
Chubb
Medtronic
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot